Deciphera Pharmaceuticals, Inc.
DCPHN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
7
Phase 3 Programs
4
Upcoming Catalysts
5
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
DCPH News
Catalyst Timeline
5 upcoming, 0 past
Drug Pipeline
Sunitinib
Gastrointestinal Stromal Tumors
Ripretinib
GIST
Vimseltinib
Chronic Graft-Versus-Host Disease (cGVHD)
DCC-2618
Gastrointestinal Stromal Tumors
DCC-3084
Advanced Solid Tumor
DCC-3009
Gastrointestinal Stromal Tumor (GIST)
Inlexisertib
Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Sunitinib | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
Ripretinib | Phase 3 | GIST | - | - |
Vimseltinib | Phase 3 | Chronic Graft-Versus-Host Disease (cGVHD) | - | - |
DCC-2618 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
DCC-3084 | Phase 2 | Advanced Solid Tumor | - | - |
DCC-3009 | Phase 2 | Gastrointestinal Stromal Tumor (GIST) | - | - |
Inlexisertib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply